Joshua Bartch

Understanding The Psilocybin Supply Chain: Every Production Method Explained
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Mydecine To Spin-Out Its U.S. Cannabis Assets By Mid July
Mydecine Unveils Four Psychedelic Drug Candidates

Joshua Bartch Recent News

Psychedelics Companies Are Seeking Opportunities In The Functional Mushroom Market
In recent years mushrooms left their dark, hidden habitats to jump into the spotlight of consumer markets. A hunger for natural foods and wellness products propelled consumers to explore the realm of fungi as a source of nutrition and wellness, as well as a means to achieving physical and mental optimization.
'Psyched': Compass IPO, UC Berkeley's Psychedelics Center, Jaguar Health's Entheogen Initiative
Compass IPO Begins Trading on NASDAQ Following a NASDAQ filing earlier this month, UK-based psychedelics research company Compass Pathways began trading under the symbol CMPS on Friday.
'Psyched': MindMed Acquires Rights For LSD Research, NewLeaf Brands To Purchase Mushroom Company
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.